Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,990
  • Shares Outstanding, K 1,138
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,290 K
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.52
Trade PHIO with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 128.63%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,226.10% on 12/14/22
  • IV Low 0.00% on 02/02/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 204
  • Open Int (30-Day) 266

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -3.24
  • Number of Estimates 1
  • High Estimate -3.24
  • Low Estimate -3.24
  • Prior Year -3.00
  • Growth Rate Est. (year over year) -8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.32 +42.32%
on 01/03/23
9.42 -34.71%
on 01/06/23
+1.69 (+37.77%)
since 12/30/22
3-Month
3.90 +57.69%
on 12/29/22
9.42 -34.71%
on 01/06/23
-0.90 (-12.83%)
since 11/02/22
52-Week
3.90 +57.69%
on 12/29/22
29.04 -78.82%
on 04/08/22
-4.41 (-41.76%)
since 02/02/22

Most Recent Stories

More News
Phio Pharmaceuticals Announces Reverse Stock Split

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...

PHIO : 6.15 (+0.16%)
Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco

/PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to...

PHIO : 6.15 (+0.16%)
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced their clinical development partner, AgonOx, Inc. has received confirmation from the...

PHIO : 6.15 (+0.16%)
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

/PRNewswire/ -- Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its...

PHIO : 6.15 (+0.16%)
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates

Phio Pharmaceuticals Corp. (PHIO) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

PHIO : 6.15 (+0.16%)
AUGX : 1.6800 (+6.33%)
Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), today announced new appointments to the leadership team, reported its financial results for the...

PHIO : 6.15 (+0.16%)
Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th

/PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology makes immune...

PHIO : 6.15 (+0.16%)
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock

Phio Pharmaceuticals Corp. (PHIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PHIO : 6.15 (+0.16%)
PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US

The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down....

RHHBY : 37.6600 (-1.72%)
PTCT : 47.36 (-0.02%)
FUSN : 3.33 (+4.72%)
PHIO : 6.15 (+0.16%)
Humana (HUM) Brings Affordable MA Plan to U.S. Veterans

Humana (HUM) ties up with USAA Life to develop a Medicare Advantage plan that transcends the VA system to fetch added healthcare benefits for veterans.

HUM : 489.77 (-4.58%)
PHIO : 6.15 (+0.16%)
SWAV : 189.49 (-0.98%)
ELV : 480.41 (-3.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation,...

See More

Key Turning Points

3rd Resistance Point 6.72
2nd Resistance Point 6.60
1st Resistance Point 6.38
Last Price 6.15
1st Support Level 6.04
2nd Support Level 5.92
3rd Support Level 5.70

See More

52-Week High 29.04
Fibonacci 61.8% 19.44
Fibonacci 50% 16.47
Fibonacci 38.2% 13.50
Last Price 6.15
52-Week Low 3.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar